Article Abstract

What is the optimal adjuvant therapy for T3N0 lung cancer invading the chest wall?

Authors: Makoto Suzuki, Takeshi Mori, Kenji Shiraishi, Koei Ikeda, Yoshiko Masuda, Eri Matsubara, Chika Shirakami, Hironori Hinokuma

Abstract

Even after complete removal of stage I–III non-small cell lung cancer (NSCLC), relapse is common. Adjuvant treatment has been the focus of efforts to improve overall survival (OS) of patients who undergo complete resection of stage I–III NSCLC.